Comparison of empirical cefazolin versus vancomycin on outcomes of peritoneal dialysis-associated peritonitis: a propensity-score-matched study
10.3760/cma.j.cn441217-20241202-01201
- VernacularTitle:经验性头孢唑林与万古霉素对腹膜透析相关性腹膜炎预后影响的比较：一项倾向性评分匹配分析
- Author:
Yumeng QIAO
1
;
Shuang GAO
1
;
Tiantian MA
1
;
Zhikai YANG
1
;
Jie DONG
1
Author Information
1. 北京大学第一医院肾内科 北京大学肾脏病研究所 国家卫生健康委员会肾脏疾病重点实验室 教育部慢性肾脏病防治重点实验室 重症肾脏疾病精准诊疗药械研发北京市重点实验室，北京100034
- Publication Type:Journal Article
- Keywords:
Peritoneal dialysis;
Peritonitis;
Prognosis;
Cefazolin;
Vancomycin
- From:
Chinese Journal of Nephrology
2025;41(11):833-840
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the effect of empirical cefazolin and vancomycin on the adverse outcomes in peritoneal dialysis (PD)-associated peritonitis patients.Methods:This was a retrospective analysis of a single-centre prospective cohort. Clinical data of consecutive PD-related peritonitis episodes occurring for the first time in patients (≥18 years) between January 1, 2008 and December 31, 2021 were reviewed. Patients were classified into a cefazolin group or a vancomycin group according to the empirical antibiotic regimen. The primary endpoint was peritonitis-related death within 1 month of onset and the secondary endpoint was transfer to haemodialysis for peritonitis-related reasons within the same period. Differences in both endpoints between the two regimens were analysed in the overall population and in the Gram-positive peritonitis subgroup. Univariable and multivariable logistic regression models were used to estimate the risk of adverse outcomes associated with antibiotic choice. Propensity-score matching was performed to control for confounding bias.Results:A total of 516 eligible PD patients developed peritonitis during the study period were included, among whom 138 received empirical cefazolin and 322 received vancomycin. Baseline characteristics were significantly different between the cefazolin and vancomycin groups, including annual income >50 000 yuan ( χ2=17.854, P<0.001), cardiovascular disease history ( χ2=3.909, P=0.048), prior peritonitis history ( χ2=18.327, P<0.001), serum albumin ( t=2.430, P=0.013), triglycerides ( Z=-3.108, P=0.002), total cholesterol ( t=3.752, P<0.001), phosphate ( t=3.362, P=0.002) and sodium ( t=3.021, P=0.004). Neither peritonitis-related mortality nor transfer to haemodialysis differed between the cefazolin and vancomycin groups in the overall cohort or in the Gram-positive peritonitis subgroup (all P>0.05). Logistic regression analysis (univariable and multivariable) showed that empirical vancomycin was not associated with a higher risk of adverse outcome when compared with cefazolin in the overall cohort or in the Gram-positive peritonitis subgroup (all P>0.05). After propensity-score matching, results remained consistent (all P>0.05). Conclusion:Empirical cefazolin and vancomycin yield similar rates of short-term adverse outcomes in patients with PD-associated peritonitis, including those caused by Gram-positive organisms.
